QUBT · Quantum Computing Inc.

The thesis

Quantum Computing Inc. still has to turn its $42.5 million contract backlog into Q3 2026 revenue above Q2's $5.551 million with positive gross profit, and the shares have fallen below the level that ended the prior read. The quarterly report, estimated for 9 November to 13 November 2026 and not confirmed by the company, settles it. The shares closed at $6.59 on 22 October 2026 (adjusted daily close), 60.6% under the 52-week high of $16.71.

The prior note set a weekly-close line at $7.30, the floor of the July 2026 trading range. The 22 October 2026 daily close is $0.71 under it. The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, is 27.7, and the shares are down 17.2% over three months.

The narrative is maturing: Dirac-3S product news on 1 October 2026 and a drug-research partnership on 14 October 2026 added headlines, yet the shares kept falling. The 14 October 2026 INmune Bio announcement names a first commercial customer in pharmaceuticals and biotechnology, with options for further work and no disclosed contract value.

Bullish and bearish views on Quantum Computing Inc.

The bull case on Quantum Computing Inc. (QUBT), in brief: Backlog supplies a conversion test. The bear case: Price has broken the prior floor.

Bull case

• Backlog supplies a conversion test. The Q2 2026 results release of 10 August 2026 reported about $42.5 million of contract backlog at 30 June 2026. Q2 revenue of $5.551 million beat the $5.152 million estimate cited by Benzinga.
• A pharmaceutical customer now exists. INmune Bio and the company announced on 14 October 2026 a collaboration using the Dirac-3S machine to screen new disease uses for INmune Bio's Alzheimer's drug candidate XPro. The announcement calls the first phase the company's first commercial customer in pharmaceuticals and biotechnology.
• Chip-fabrication capacity is owned. The NHanced Semiconductors acquisition closed on 23 June 2026 for $73.1 million ($68.1 million cash plus $5.0 million stock), plus a $72 million performance earnout.

• Dirac-3S has a shipment date. The company guided on 1 October 2026 to initial shipments in November 2026. Ascendiant Capital kept a Buy rating with a $32 target on 26 August 2026.

Bear case

• Price has broken the prior floor. The 22 October 2026 close of $6.59 is under the $7.30 July 2026 range floor, and the 14-day RSI was 10.4 on 9 October 2026 before the latest decline.
• Gross profit has not cleared. Cost of revenue exceeded revenue in Q2 2026 (Q2 10-Q). The report does not separate organic from acquired revenue after the February, March and June 2026 acquisitions.
• Announcements carry no revenue figures. The 14 September 2026 Hamad Bin Khalifa University framework and the 14 October 2026 INmune Bio collaboration disclose no contract value or revenue timetable.
• Dilution room remains. The company had 226,346,861 shares outstanding at 7 August 2026, and the 2026 annual meeting authorized 450,000,000 common shares.
• Analysts are split. Cantor Fitzgerald kept a Neutral rating with a $10 target on 11 August 2026. The consensus Q3 loss is about $0.07 per share from two estimates, per Earnings Whispers.

Price setup

The shares closed at $6.59 on 22 October 2026. That compares with $7.44 on 9 October 2026, $8.96 on the weekly close of 25 September 2026 and the 52-week high of $16.71. Each reference is an adjusted daily or weekly close.

A figure that large can lift the shares sharply on good news and deepen a decline on bad news. No newer settlement figure was available.

A daily close below $6.00 would extend the break below the July range. The 14-day RSI of 27.7 shows heavy selling without any sign yet that it has stopped.

Catalysts, next 30 days

• 9 November 2026 to ~13 November 2026 (est.): Q3 2026 results. Earnings Whispers lists 9 November 2026 after the close; the 13 November 2026 date comes from MarketBeat. The company has not confirmed either. Revenue against $5.551 million and cost of revenue against revenue decide whether backlog converts.

Elapsed catalysts

• ~2026-11 (date unconfirmed): First Dirac-3S shipments, per company guidance of 1 October 2026. A shipment would be the first dated sales evidence for the machine. (passed 36d ago)

What would change the view

The case breaks if Q3 2026 revenue is at or below Q2's $5.551 million, or if cost of revenue again exceeds revenue. Either result would show the backlog is not converting into profitable sales. A Q3 10-Q share count well above the 226,346,861 reported at 7 August 2026, or a new offering, would add dilution to that.

A daily close below $6.00 would take the shares to new lows for the move and end the case on price. A disclosed dollar value for the INmune Bio work, or dated Dirac-3S shipments, would strengthen it.

What it trades with

The shares trade with other small Quantum computing and photonics companies and with retail momentum names. Heavy short interest of 32.31% of float at 15 September 2026 ties moves to attention shifts as much as to company results. No peer price data is cited here.